Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Breaking Down Steve Cohen’s Four Latest Moves in Sarepta Therapeutics (SRPT), Smith & Wesson (SWHC), More

Page 1 of 2

Steve Cohen‘s Point72 Asset Management has upped its stake in two companies and added two new holdings to its equity portfolio, according to four separate Schedule 13G forms filed with the SEC recently. Firstly, an additional 642,300 shares of Sarepta Therapeutics Inc (NASDAQ:SRPT) were acquired, taking the total ownership to the company to over 2.19 million shares. Cohen’s Smith & Wesson Holding Corp (NASDAQ:SWHC) holding was increased to just under 2.70 million shares through the addition of about 1.76 million shares. Moreover, a new stake in Trillium Therapeutics Inc. (NASDAQ:TRIL) was initiated, consisting of 378,050 shares, representing 5.6% of the company’s outstanding stock. Finally, another new stake was initiated in CONN’S, Inc. (NASDAQ:CONN) of over 1.82 million shares, constituting about 5% of the company’s outstanding shares. The stakes were acquired through various affiliated funds of Point72.

Steven Cohen

Point72 Asset Management, formerly known as SAC Capital Advisors, was founded in 1992 with $25 million in assets. The hedge fund’s name was changed in 2014 as Cohen wanted to distance his firm from the negative publicity that it was embroiled in pertaining to one of the biggest insider-trading scandals in the history of the hedge fund industry, which ended with SAC paying a total of $1.8 billion in penalties. The new fund has about $10 billion in assets and is a family office, managing the money of only Cohen, his family members, and certain employees. The market value of Point72’s equity portfolio stood at $14.25 billion at the end of the first quarter. Holdings in the consumer discretionary and energy sectors contributed 21% and 17% respectively to the above value.

Insider Monkey tracks hedge funds’ moves in order to identify actionable patterns and profit from them. Our research has shown that hedge funds’ large-cap stock picks historically delivered a monthly alpha of six basis points, though these stocks underperformed the S&P 500 Total Return Index by an average of seven basis points per month between 1999 and 2012. These stocks were able to generate alpha because of their lower risk profile. On the other hand, the 15 most popular small-cap stocks among hedge funds outperformed the S&P 500 Index by an average of 95 basis points per month. These stocks were slightly riskier, so their monthly alpha was 80 basis points (read the details here). We believe investors will be better off by focusing on small-cap stocks rather than large-cap stocks.

Cohen’s new holding in Sarepta Therapeutics Inc (NASDAQ:SRPT) represents 5.3% of the company’s outstanding stock. Point72 also holds call options on 275,200 of Sarepta’s shares. Down by about 8.29% year-to-date, the $526.23 million biopharmaceutical company is focused on developing RNA-based therapeutics. Sarepta Therapeutics Inc (NASDAQ:SRPT)’s leading treatment is eteplirsen, a program for Duchenne muscular dystrophy. After the resignation of former CEO and President Christopher Garabedian, the company recently appointed its Chief Medical Officer Edward Kaye as its interim CEO. According to our database, Joseph Edelman is the largest stockholder of Sarepta Therapeutics Inc (NASDAQ:SRPT), as he held some 2.81 million shares at the end of the first quarter.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!